Current management of hepatocellular carcinoma: an Eastern perspective
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer death, especially in Eastern areas. With advancements in diagnosis and treatment modalities for HCC, the survival and prognosis of HCC patients are improving. However, treatment patterns are not uniform between areas despite effor...
Uloženo v:
| Vydáno v: | World journal of gastroenterology : WJG Ročník 21; číslo 13; s. 3826 |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
United States
07.04.2015
|
| Témata: | |
| ISSN: | 2219-2840, 2219-2840 |
| On-line přístup: | Zjistit podrobnosti o přístupu |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Hepatocellular carcinoma (HCC) is one of the leading causes of cancer death, especially in Eastern areas. With advancements in diagnosis and treatment modalities for HCC, the survival and prognosis of HCC patients are improving. However, treatment patterns are not uniform between areas despite efforts to promote a common protocol. Although many hepatologists in Asian countries may adopt the principles of the Barcelona Clinic Liver Cancer staging system, they are also independently making an effort to expand the indications of each treatment and to combine therapies for better outcomes. Several expanded criteria for liver transplantation in HCC have been developed in Asian countries. Living donor liver transplantation is much more commonly performed in these countries than deceased donor liver transplantation, and it may be preceded by other treatments such as the down-staging of tumors. Local ablation therapies are often combined with transarterial chemoembolization (TACE) and the outcome is comparable to that of surgical resection. The indications of TACE are expanding, and there are new types of transarterial therapies. Although data on drug-eluting beads, TACE, and radioembolization in Asian countries are still relatively sparse compared with Western countries, these methods are gradually gaining popularity because of better tolerability and the possibility of improved response rates. Hepatic arterial infusion chemotherapy and radiotherapy are not included in Western guidelines, but are currently being used actively in several Asian countries. For more advanced HCCs, appropriate combinations of TACE, radiotherapy, and sorafenib can be considered, and emerging data indicate improved outcomes of combination therapies compared with single therapies. To include these paradigm shifts into newer treatment guidelines, more studies may be needed, but they are certainly in progress. |
|---|---|
| AbstractList | Hepatocellular carcinoma (HCC) is one of the leading causes of cancer death, especially in Eastern areas. With advancements in diagnosis and treatment modalities for HCC, the survival and prognosis of HCC patients are improving. However, treatment patterns are not uniform between areas despite efforts to promote a common protocol. Although many hepatologists in Asian countries may adopt the principles of the Barcelona Clinic Liver Cancer staging system, they are also independently making an effort to expand the indications of each treatment and to combine therapies for better outcomes. Several expanded criteria for liver transplantation in HCC have been developed in Asian countries. Living donor liver transplantation is much more commonly performed in these countries than deceased donor liver transplantation, and it may be preceded by other treatments such as the down-staging of tumors. Local ablation therapies are often combined with transarterial chemoembolization (TACE) and the outcome is comparable to that of surgical resection. The indications of TACE are expanding, and there are new types of transarterial therapies. Although data on drug-eluting beads, TACE, and radioembolization in Asian countries are still relatively sparse compared with Western countries, these methods are gradually gaining popularity because of better tolerability and the possibility of improved response rates. Hepatic arterial infusion chemotherapy and radiotherapy are not included in Western guidelines, but are currently being used actively in several Asian countries. For more advanced HCCs, appropriate combinations of TACE, radiotherapy, and sorafenib can be considered, and emerging data indicate improved outcomes of combination therapies compared with single therapies. To include these paradigm shifts into newer treatment guidelines, more studies may be needed, but they are certainly in progress.Hepatocellular carcinoma (HCC) is one of the leading causes of cancer death, especially in Eastern areas. With advancements in diagnosis and treatment modalities for HCC, the survival and prognosis of HCC patients are improving. However, treatment patterns are not uniform between areas despite efforts to promote a common protocol. Although many hepatologists in Asian countries may adopt the principles of the Barcelona Clinic Liver Cancer staging system, they are also independently making an effort to expand the indications of each treatment and to combine therapies for better outcomes. Several expanded criteria for liver transplantation in HCC have been developed in Asian countries. Living donor liver transplantation is much more commonly performed in these countries than deceased donor liver transplantation, and it may be preceded by other treatments such as the down-staging of tumors. Local ablation therapies are often combined with transarterial chemoembolization (TACE) and the outcome is comparable to that of surgical resection. The indications of TACE are expanding, and there are new types of transarterial therapies. Although data on drug-eluting beads, TACE, and radioembolization in Asian countries are still relatively sparse compared with Western countries, these methods are gradually gaining popularity because of better tolerability and the possibility of improved response rates. Hepatic arterial infusion chemotherapy and radiotherapy are not included in Western guidelines, but are currently being used actively in several Asian countries. For more advanced HCCs, appropriate combinations of TACE, radiotherapy, and sorafenib can be considered, and emerging data indicate improved outcomes of combination therapies compared with single therapies. To include these paradigm shifts into newer treatment guidelines, more studies may be needed, but they are certainly in progress. Hepatocellular carcinoma (HCC) is one of the leading causes of cancer death, especially in Eastern areas. With advancements in diagnosis and treatment modalities for HCC, the survival and prognosis of HCC patients are improving. However, treatment patterns are not uniform between areas despite efforts to promote a common protocol. Although many hepatologists in Asian countries may adopt the principles of the Barcelona Clinic Liver Cancer staging system, they are also independently making an effort to expand the indications of each treatment and to combine therapies for better outcomes. Several expanded criteria for liver transplantation in HCC have been developed in Asian countries. Living donor liver transplantation is much more commonly performed in these countries than deceased donor liver transplantation, and it may be preceded by other treatments such as the down-staging of tumors. Local ablation therapies are often combined with transarterial chemoembolization (TACE) and the outcome is comparable to that of surgical resection. The indications of TACE are expanding, and there are new types of transarterial therapies. Although data on drug-eluting beads, TACE, and radioembolization in Asian countries are still relatively sparse compared with Western countries, these methods are gradually gaining popularity because of better tolerability and the possibility of improved response rates. Hepatic arterial infusion chemotherapy and radiotherapy are not included in Western guidelines, but are currently being used actively in several Asian countries. For more advanced HCCs, appropriate combinations of TACE, radiotherapy, and sorafenib can be considered, and emerging data indicate improved outcomes of combination therapies compared with single therapies. To include these paradigm shifts into newer treatment guidelines, more studies may be needed, but they are certainly in progress. |
| Author | Yim, Hyung Joon Suh, Sang Jun Um, Soon Ho |
| Author_xml | – sequence: 1 givenname: Hyung Joon surname: Yim fullname: Yim, Hyung Joon organization: Hyung Joon Yim, Sang Jun Suh, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Korea University Ansan Hospital, Ansan-si 425-707, Gyeonggi-do, South Korea – sequence: 2 givenname: Sang Jun surname: Suh fullname: Suh, Sang Jun organization: Hyung Joon Yim, Sang Jun Suh, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Korea University Ansan Hospital, Ansan-si 425-707, Gyeonggi-do, South Korea – sequence: 3 givenname: Soon Ho surname: Um fullname: Um, Soon Ho organization: Hyung Joon Yim, Sang Jun Suh, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Korea University Ansan Hospital, Ansan-si 425-707, Gyeonggi-do, South Korea |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/25852267$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNT0tLw0AYXKRiH3r3JDl6Scx--8iuNwmtCgUveg7bzZeakmziblLpv7fFCp5mmBmGmTmZuM4hIbc0TVjG1cP3bpvsgSY1ZQlTIC_IDIDqGBRPJ__4lMxD2KUpMCbgikxBKAEgsxlZ5aP36IaoNc5ssT3Rroo-sTdDZ7Fpxsb4yBpva9e15jEyLlqaMKB3UY8-9GiHeo_X5LIyTcCbMy7Ix2r5nr_E67fn1_xpHVvO0yG2mQQqtGQyK2mlDFVKyRQrzfhRZgo1MISNtKVSHI9WaYXeoOJZVlWl4LAg97-9ve--RgxD0dbhNNM47MZQUKk4By1AH6N35-i4abEsel-3xh-Kv-_wAyOdXW0 |
| CitedBy_id | crossref_primary_10_3892_ol_2016_4694 crossref_primary_10_3389_fonc_2020_01319 crossref_primary_10_1080_21691401_2020_1813740 crossref_primary_10_1111_ajco_13361 crossref_primary_10_1016_j_hbpd_2023_12_001 crossref_primary_10_3390_livers3010011 crossref_primary_10_1002_cld_513 crossref_primary_10_1016_j_acra_2017_10_018 crossref_primary_10_1097_MD_0000000000011872 crossref_primary_10_1097_JS9_0000000000000376 crossref_primary_10_3748_wjg_v22_i34_7806 crossref_primary_10_1038_s41598_018_31351_3 crossref_primary_10_1186_s40001_023_01310_4 crossref_primary_10_1080_13645706_2021_1986724 crossref_primary_10_1007_s00595_017_1603_x crossref_primary_10_1371_journal_pone_0223678 crossref_primary_10_1016_j_jep_2016_05_055 crossref_primary_10_3892_mmr_2017_7275 crossref_primary_10_1016_j_micpath_2017_04_028 crossref_primary_10_1007_s00432_022_04338_x crossref_primary_10_1007_s00261_021_03248_9 crossref_primary_10_3727_096504016X14742891049073 crossref_primary_10_1111_jcmm_13964 crossref_primary_10_1111_liv_14972 crossref_primary_10_1186_s12935_016_0332_3 crossref_primary_10_1002_jso_24215 crossref_primary_10_1007_s12094_023_03232_3 crossref_primary_10_1111_jcmm_14197 crossref_primary_10_3748_wjg_v21_i42_12059 crossref_primary_10_1111_liv_15130 crossref_primary_10_3390_medicina60061010 crossref_primary_10_1186_s12893_021_01065_x crossref_primary_10_1186_s12951_024_02808_7 crossref_primary_10_3892_or_2016_4742 crossref_primary_10_3390_molecules26175185 crossref_primary_10_1007_s10330_018_0299_9 crossref_primary_10_1055_s_0045_1805803 crossref_primary_10_3389_fphar_2018_00268 crossref_primary_10_1111_jgh_13783 crossref_primary_10_1186_s12885_022_10361_5 crossref_primary_10_3390_cancers10120516 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.3748/wjg.v21.i13.3826 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| EISSN | 2219-2840 |
| ExternalDocumentID | 25852267 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Review |
| GeographicLocations | Asia |
| GeographicLocations_xml | – name: Asia |
| GroupedDBID | --- 123 29R 2WC 36B 53G 5VR 8WL AAKDD ACGFO AENEX AFUIB ALMA_UNASSIGNED_HOLDINGS CCEZO CGR CHBEP CIEJG CS3 CUY CVF CW9 DIK DU5 E3Z EBS ECM EIF EJD F5P FRP GX1 HYE NPM OK1 P2P RNS RPM TR2 XSB 7X8 |
| ID | FETCH-LOGICAL-c440t-c7621596367d1f8a188860ef93415938e923e2b6cd884e860dc59be8477ffd542 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 51 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000352852700007&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2219-2840 |
| IngestDate | Tue Nov 04 14:32:15 EST 2025 Mon Jul 21 06:04:22 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | false |
| IsScholarly | true |
| Issue | 13 |
| Keywords | Hepatocellular carcinoma Eastern Treatment Combination Guidelines |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c440t-c7621596367d1f8a188860ef93415938e923e2b6cd884e860dc59be8477ffd542 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| OpenAccessLink | https://www.wjgnet.com/1007-9327/full/v21/i13/3826.htm |
| PMID | 25852267 |
| PQID | 1684429529 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_1684429529 pubmed_primary_25852267 |
| PublicationCentury | 2000 |
| PublicationDate | 2015-04-07 |
| PublicationDateYYYYMMDD | 2015-04-07 |
| PublicationDate_xml | – month: 04 year: 2015 text: 2015-04-07 day: 07 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | World journal of gastroenterology : WJG |
| PublicationTitleAlternate | World J Gastroenterol |
| PublicationYear | 2015 |
| SSID | ssj0023352 |
| Score | 2.3534598 |
| SecondaryResourceType | review_article |
| Snippet | Hepatocellular carcinoma (HCC) is one of the leading causes of cancer death, especially in Eastern areas. With advancements in diagnosis and treatment... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 3826 |
| SubjectTerms | Asia - epidemiology Asian People Carcinoma, Hepatocellular - diagnosis Carcinoma, Hepatocellular - ethnology Carcinoma, Hepatocellular - mortality Carcinoma, Hepatocellular - therapy Combined Modality Therapy Guideline Adherence Humans Liver Neoplasms - diagnosis Liver Neoplasms - ethnology Liver Neoplasms - mortality Liver Neoplasms - therapy Practice Guidelines as Topic Practice Patterns, Physicians' - standards Practice Patterns, Physicians' - trends Treatment Outcome |
| Title | Current management of hepatocellular carcinoma: an Eastern perspective |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/25852267 https://www.proquest.com/docview/1684429529 |
| Volume | 21 |
| WOSCitedRecordID | wos000352852700007&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3NS8MwFA_qPHjxA7_mFxG8ZmuTtEm8iMiGBx07qOxW0jTRCWurm_Pf96XttpMgeGmhpRBeX37v9z7yHkJXEXhc2veplMwFxLd8I6nhKYmsNR4zua3Gt708iMFAjkZq2ATcpk1Z5QITK6DOCuNj5N0wlhywM6LqpvwgfmqUz642IzTWUYsBlfFaLUbLLAL154n8cDnYlQRgOKjTlL7hSvf7_bUzp2FnHLIOkzT-nWBWhqa_898l7qLthmLi21on9tCazfdRv2nEhCfLehdcOPwG1mhW-Oi9L0fFxk8WyouJvsY6xz1ddVHA5epA5gF67vee7u5JM0OBGM6DGTEAdsBYYhaLLHRSh-DxxoF1CqxXpJi0QPAsTWOTScktvMpMpFILNks4l0WcHqKNvMjtMcKCWsWVNmkGz1O4B45pYE-OKSCFmW2jy4VYEtBRv3Sd2-JrmqwE00ZHtWyTsm6mkVDwV4ACipM_fH2KtoCvRFXhjDhDLQc71J6jTTOfjaefF9XPh-tg-PgDuAS5aw |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Current+management+of+hepatocellular+carcinoma%3A+an+Eastern+perspective&rft.jtitle=World+journal+of+gastroenterology+%3A+WJG&rft.au=Yim%2C+Hyung+Joon&rft.au=Suh%2C+Sang+Jun&rft.au=Um%2C+Soon+Ho&rft.date=2015-04-07&rft.issn=2219-2840&rft.eissn=2219-2840&rft.volume=21&rft.issue=13&rft.spage=3826&rft_id=info:doi/10.3748%2Fwjg.v21.i13.3826&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2219-2840&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2219-2840&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2219-2840&client=summon |